Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Chemotherapy in KEAP1-mutated NSCLC
NCT06341660Phase 2Recruiting
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- May 2023
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Guangzhou Institute of Respiratory Health. Started May 2023; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06341660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341660.